HC Wainwright Reiterates Buy Rating for United Therapeutics (NASDAQ:UTHR)

United Therapeutics (NASDAQ:UTHR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $425.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 32.83% from the stock’s current price.

UTHR has been the topic of several other reports. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group increased their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Trading Down 1.1 %

Shares of United Therapeutics stock opened at $319.96 on Thursday. The business’s 50 day simple moving average is $359.65 and its 200-day simple moving average is $360.46. The stock has a market capitalization of $14.28 billion, a price-to-earnings ratio of 14.05, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics has a twelve month low of $221.53 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same period last year, the firm earned $4.36 EPS. Sell-side analysts predict that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at $13,743,122.70. This represents a 17.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,164 shares of company stock valued at $45,278,893. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $25,000. Brooklyn Investment Group bought a new position in United Therapeutics during the third quarter worth $33,000. Dunhill Financial LLC raised its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after buying an additional 50 shares during the last quarter. State of Wyoming bought a new stake in United Therapeutics in the fourth quarter valued at $62,000. Finally, Millstone Evans Group LLC bought a new stake in United Therapeutics in the fourth quarter valued at $67,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.